Lycia Therapeutics, Inc. Chief Business Officer Sofia Touami filed a Form 4 on October 26, 2026, disclosing the acquisition of stock options granted on August 11, 2026, prior to the company's initial public offering.

Key Highlights

  • Reporting person: Sofia Touami, Chief Business Officer of Lycia Therapeutics, Inc. (NASDAQ:LYCA)
  • Transaction: Acquisition (Code A) of 68,755 stock options (right to buy) on August 11, 2026
  • Exercise price: $3.70 per share, with an expiration date of August 10, 2036
  • Derivative securities owned after transaction: 68,755 stock options, held directly
  • Vesting schedule: Options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026, subject to continued service
  • Pre-IPO transaction: The filing notes the transaction occurred before the issuer's registration of a class of equity securities under Section 12 of the Exchange Act, reported pursuant to Rule 16a-2(a)
  • Price of derivative security: $0

Sofia Touami's Pre-IPO Option Grant at Lycia Therapeutics

According to the Form 4 filing, Sofia Touami, serving as Chief Business Officer of Lycia Therapeutics, Inc. (NASDAQ:LYCA), acquired 68,755 stock options on August 11, 2026. The options, which carry an exercise price of $3.70 per share and are exercisable for shares of common stock, were reported at a price of $0. The options expire on August 10, 2036, giving a ten-year window from the grant date.

The filing states that "the transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering," and that the transaction is reported pursuant to Rule 16a-2(a). Following the reported transaction, Touami directly holds 68,755 derivative securities. No non-derivative securities are reported in Table I of the filing.

The filing further discloses that the options vest as to 1/48 of the total award monthly over four years, with the first tranche having vested on September 6, 2026, subject to the reporting person's continued provision of service to the issuer on each vesting date. The Form 4 was signed by Amy Bachrodt as Attorney-in-Fact on October 26, 2026.

What Was Disclosed

Lycia Therapeutics Chief Business Officer Sofia Touami disclosed the acquisition of 68,755 stock options at an exercise price of $3.70, granted August 11, 2026, before the company's IPO, vesting monthly over four years, and expiring August 10, 2036.